Skip to content
Investing

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Phase 3 Survival Miss

The FDA has rejected Summit Therapeutics' lung cancer drug ivonescimab, saying slower tumour growth in the phase 3 HARMONi trial was not enough without a clear gain in survival.

The main entrance of FDA Building 1 on the agency's campus in Silver Spring, Maryland, which houses the offices of the commissioner and senior staff.
Photo: U.S. Food and Drug Administration, Wikimedia Commons, public domain

The US Food and Drug Administration has turned down Summit Therapeutics' lung cancer drug ivonescimab, saying that holding tumours back for longer is not enough without proof that patients live longer. The agency sent Summit a complete response letter, its formal refusal, on an application to use the drug with chemotherapy in advanced lung cancer. It is a setback for a medicine that Summit licensed from its Chinese developer, Akeso, in a deal worth up to $5bn.

Ivonescimab and the FDA

  • 0.76 overall survival hazard ratio from a later, post hoc look at the HARMONi trial
  • 7.3% of patients stopped ivonescimab because of treatment-related side effects, against 5.0% on placebo
  • $5bn top potential value of Summit's licence deal with Akeso

The FDA wanted proof that patients live longer

Summit had asked the FDA to approve ivonescimab with platinum-based chemotherapy for patients with EGFR-mutated non-small cell lung cancer that is locally advanced or has spread, and whose disease had already been treated with a third-generation EGFR tyrosine kinase inhibitor, a type of targeted drug. A complete response letter means the application cannot be approved in its current form.

The reasoning, as Summit described it, was simple. The drug improved progression-free survival, but without a statistically significant gain in overall survival, the FDA said, that did not establish substantial evidence that it works. Nor did it show a favourable balance of benefit and risk for this use.

The two measures sound alike but answer different questions. Progression-free survival tracks how long patients live before the cancer grows or spreads. Overall survival tracks how long they live, full stop. A drug can slow a tumour without moving the second number.

Summit pushed back on the bar itself. It said no regimen approved by the FDA has shown a statistically significant survival benefit in this setting.

Summit Therapeutics in the three months to 16 November 2026. Daily closing prices from exchange data.
Summit Therapeutics in the three months to 16 November 2026. Daily closing prices from exchange data.

The survival result leaned the right way but missed the mark

HARMONi was a global phase 3 trial, randomised and double-blind, meaning neither patients nor doctors knew who was getting the drug. Everyone received platinum chemotherapy; one group also got ivonescimab and the other a placebo. That design isolates what the new drug adds.

The trial had two primary goals, and it hit one: progression-free survival improved significantly. Summit said a post hoc analysis with longer follow-up for Western patients showed a benefit of similar size.

Survival was the sticking point. The main overall survival analysis favoured ivonescimab on the numbers but fell short of statistical significance. In the post hoc analysis, Summit reported a hazard ratio of 0.76 in the whole study population, in Asian patients and in Western patients alike. Put simply, patients on ivonescimab had roughly a 24% lower risk of dying over the follow-up period than those on chemotherapy alone.

"Post hoc" is the catch. It means the analysis was run after the fact, outside the test the trial was built around, so it does not count as formal proof. The FDA's stated reasoning rested on the missing significant result.

Summit said the safety profile matched earlier studies, with no new safety signals.

Safety in HARMONiIvonescimab plus chemotherapyPlacebo plus chemotherapy
Stopped study drug due to treatment-related side effects16 patients (7.3%)11 patients (5.0%)
Deaths from treatment-related side effects4 patients (1.8%)5 patients (2.3%)

A drug built to hit two targets at once

Ivonescimab is a bispecific antibody: one molecule aimed at two targets. The first is PD-1, a checkpoint that tumours exploit to switch off the immune system's attack. The second is VEGF, a signal that helps tumours grow new blood vessels. According to Summit, the antibody has four binding sites and grips PD-1 more tightly when VEGF is present.

Akeso, which is listed in Hong Kong, developed the drug, and China granted its first approval in May 2024. Akeso calls it the world's first approved bispecific antibody that combines immunotherapy and blood-vessel blocking in a single molecule. It has licensed the rights in the US and Canada, South America, Europe, the Middle East, Africa and Japan to Summit.

Maky Zanganeh, Summit's president and co-chief executive, made the case for more treatment choice from experience. "As a cancer survivor, I understand firsthand how important it is for patients to have access to multiple treatment options, particularly when they are facing diseases with significant unmet medical needs," she said.

The bigger tests are still to come

The letter covers one narrow use, in patients whose cancer has already been treated. Summit is also testing ivonescimab earlier, as a first treatment for metastatic lung cancer, and in other tumours.

Ivonescimab trials to watch

  • HARMONi-3: ivonescimab plus chemotherapy as first-line treatment for metastatic lung cancer, with squamous and non-squamous tumours analysed separately
  • HARMONi-7: ivonescimab on its own, first-line, for lung tumours with high levels of the PD-L1 protein
  • HARMONi-GI3: ivonescimab plus chemotherapy as first-line treatment for metastatic bowel cancer that cannot be removed by surgery
  • HARMONi-GU1 and SMT112-216: combinations in untreated bladder and urinary tract cancer and in clear cell kidney cancer

In a different disease, Akeso already has the kind of result the FDA asked for. On 25 October it said its HARMONi-GI1 trial in biliary tract cancer, which affects the bile ducts and gallbladder, met its primary goal of overall survival at a pre-planned interim analysis. Patients on ivonescimab plus chemotherapy lived a median 14.9 months, against 12.1 months on durvalumab plus chemotherapy, which Akeso describes as the standard of care.

Questions and answers

Why did the FDA reject ivonescimab?

According to Summit, the FDA said the gain in progression-free survival in the HARMONi trial was not enough without a statistically significant improvement in overall survival, so substantial evidence of effectiveness was not established.

What is ivonescimab?

Ivonescimab is a bispecific antibody developed by Akeso that blocks both PD-1 and VEGF. Summit Therapeutics holds the rights in the US and Canada, South America, Europe, the Middle East, Africa and Japan.

Is ivonescimab approved anywhere?

Yes, in China, where it was first approved in May 2024. It remains an investigational drug in the US.

Sources

Related stories

Investing

Novavax Investor Profile: Sanofi Royalties, the Matrix-M Adjuvant and $627m of Cash

Novavax now earns most of its money from partners led by Sanofi. It ended September with $627m of cash and $292.1m of long-term debt; its numbers, milestones, risks and dates to…

Investing

Viking Therapeutics Investor Profile: VK2735, Two Phase 3 Programmes and $960m of Cash

Viking Therapeutics is testing obesity drug VK2735 in Phase 3 as a weekly injection and a daily pill. It had $960m of cash at the end of September but lost $183.2m in the third…

Investing

Kraig Biocraft Laboratories Profile: Spider Silk From Silkworms, Still Before Revenue

Kraig Biocraft Laboratories breeds silkworms that spin spider silk and farms them in Vietnam. It has begun shipping yarn but reported no revenue in the first half and carries a…

Investing

Red Cat Withdraws Its $150m to $180m 2026 Revenue Target After $11.8m Third Quarter

Red Cat Holdings has withdrawn its $150m to $180m revenue target for 2026 after third-quarter sales of $11.8m, blaming slower defence funding. Its quarterly net loss more than…

Investing

Aya Gold & Silver Corrects Q3 Cash Costs to $14.28 an Ounce After Silver Double Count

Aya Gold & Silver refiled its Q3 MD&A after silver in transit was deducted twice. Zgounder ounces sold rise to 1,392,478 and cash costs fall to $14.28 from $15.51. Revenue and…

Investing

Red Cat Withdraws Its $150m to $180m 2026 Revenue Target After $11.8m Third Quarter

Red Cat Holdings has withdrawn its $150m to $180m revenue target for 2026 after third-quarter sales of $11.8m, blaming slower defence funding. Its quarterly net loss more than…

Investing

Berkshire Reveals $689m Bending Spoons Stake, Doubles Lennar and Trims Bank of America Again

Berkshire Hathaway's third-quarter 13F shows a new Bending Spoons stake worth $689m, a doubled Lennar holding and 27.5 million more Bank of America shares sold, while Apple stayed…

Investing

Warren Buffett Gives 9.2 Million Berkshire Shares to Four Family Foundations at Thanksgiving

Warren Buffett, 96, is giving 9,225,000 Berkshire B shares to four family foundations, over three times last year's gift, and says his confidence in Berkshire is as strong as ever.